IP Library Granted Patent US 7,728,013
Granted Patent B2
US 7,728,013 · App. 11/431,132 · Granted Jun 1, 2010

Method of modulating stress-activated protein kinase system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,728,013
App. No.
11/431,132
Granted
Jun 1, 2010
Kind
B2
Abstract

Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

Claims (50)

1. A compound selected from the group consisting of:

15

16

17

18

19

20

21

23

25

27

28

29

30

31

32

or a pharmaceutically acceptable salt or ester thereof.

2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2 , wherein the composition contains an amount of said compound that is selected for administration to a patient on a schedule selected from: twice a day, once a day, once every two days, three times a week, twice a week, and once a week.

4. The pharmaceutical composition of claim 2 , wherein the composition consists of an amount of said compound that is selected for administration to a patient on a schedule selected from the group consisting of twice a day, once a day, once every two days, three times a week, twice a week, and once a week.

5. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

6. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

7. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

8. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

9. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

10. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

11. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

12. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

13. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

14. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

15. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

16. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

17. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

18. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

19. The compound of claim 1 having a structure

or a pharmaceutically acceptable salt or ester thereof.

Assignments (3)
CERTIFICATE OF CHANGE OF COMPANY'S ADDRESS Recorded Jul 27, 2018
From: INTERMUNE, INC.
To: INTERMUNE, INC.
Reel/Frame 046638/0466 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2009
From: KOSSEN, KARL; SEREBRYANY, VLADIMIR
To: INTERMUNE, INC.
Reel/Frame 022787/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2006
From: BLATT, LAWRENCE M.; SEIWERT, SCOTT D.; BEIGELMAN, LEONID; RADHAKRISHNAN, RAMACHANDRAN
To: INTERMUNE, INC.
Reel/Frame 018134/0206 →